{"pmid":32474135,"title":"Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic.","text":["Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic.","Patients with pre-existing cardiovascular disease and risk factors are more likely to experience adverse outcomes associated with the novel coronavirus disease-2019 (COVID-19). Additionally, consistent reports of cardiac injury and de novo cardiac complications, including possible myocarditis, arrhythmia, and heart failure in patients without prior cardiovascular disease or significant risk factors, are emerging, possibly due to an accentuated host immune response and cytokine release syndrome. As the spread of the virus increases exponentially, many patients will require medical care either for COVID-19 related or traditional cardiovascular issues. While the COVID-19 pandemic is dominating the attention of the healthcare system, there is an unmet need for a standardized approach to deal with COVID-19 associated and other traditional cardiovascular issues during this period. We provide consensus guidance for the management of various cardiovascular conditions during the ongoing COVID-19 pandemic with the goal of providing the best care to all patients and minimizing the risk of exposure to frontline healthcare workers.","Trends Cardiovasc Med","Ganatra, Sarju","Dani, Sourbha S","Shah, Sachin","Asnani, Aarti","Neilan, Tomas G","Lenihan, Daniel","Ky, Bonnie","Barac, Ana","Hayek, Salim S","Leja, Monika","Herrmann, Joerg","Thavendiranathan, Paaladinesh","Fradley, Michael","Bang, Vigyan","Shreyder, Katherine","Parikh, Rohan","Patel, Rushin","Singh, Amitoj","Brar, Simarjeet","Guha, Avirup","Gupta, Dipti","Mascari, Paolo","Patten, Richard","Venesy, David","Nohria, Anju","Resnic, Frederic S","32474135"],"abstract":["Patients with pre-existing cardiovascular disease and risk factors are more likely to experience adverse outcomes associated with the novel coronavirus disease-2019 (COVID-19). Additionally, consistent reports of cardiac injury and de novo cardiac complications, including possible myocarditis, arrhythmia, and heart failure in patients without prior cardiovascular disease or significant risk factors, are emerging, possibly due to an accentuated host immune response and cytokine release syndrome. As the spread of the virus increases exponentially, many patients will require medical care either for COVID-19 related or traditional cardiovascular issues. While the COVID-19 pandemic is dominating the attention of the healthcare system, there is an unmet need for a standardized approach to deal with COVID-19 associated and other traditional cardiovascular issues during this period. We provide consensus guidance for the management of various cardiovascular conditions during the ongoing COVID-19 pandemic with the goal of providing the best care to all patients and minimizing the risk of exposure to frontline healthcare workers."],"journal":"Trends Cardiovasc Med","authors":["Ganatra, Sarju","Dani, Sourbha S","Shah, Sachin","Asnani, Aarti","Neilan, Tomas G","Lenihan, Daniel","Ky, Bonnie","Barac, Ana","Hayek, Salim S","Leja, Monika","Herrmann, Joerg","Thavendiranathan, Paaladinesh","Fradley, Michael","Bang, Vigyan","Shreyder, Katherine","Parikh, Rohan","Patel, Rushin","Singh, Amitoj","Brar, Simarjeet","Guha, Avirup","Gupta, Dipti","Mascari, Paolo","Patten, Richard","Venesy, David","Nohria, Anju","Resnic, Frederic S"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32474135","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.tcm.2020.05.004","keywords":["covid-19","sars-cov-2","cardiovascular disease","coronavirus"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1668341932667961346,"score":9.490897,"similar":[{"pmid":32201335,"pmcid":"PMC7198856","title":"Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic.","text":["Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic.","The coronavirus disease-2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 that has significant implications for the cardiovascular care of patients. First, those with COVID-19 and preexisting cardiovascular disease (CVD) have an increased risk of severe disease and death. Second, infection has been associated with multiple direct and indirect cardiovascular complications including acute myocardial injury, myocarditis, arrhythmias and venous thromboembolism. Third, therapies under investigation for COVID-19 may have cardiovascular side effects. Fourth, the response to COVID-19 can compromise the rapid triage of non-COVID-19 patients with cardiovascular conditions. Finally, the provision of cardiovascular care may place health care workers in a position of vulnerability as they become host or vectors of virus transmission. We hereby review the peer-reviewed and preprint literature pertaining to cardiovascular considerations related to COVID-19 and highlight gaps in knowledge that require further study pertinent to patients, health care workers, and health systems.","J Am Coll Cardiol","Driggin, Elissa","Madhavan, Mahesh V","Bikdeli, Behnood","Chuich, Taylor","Laracy, Justin","Bondi-Zoccai, Giuseppe","Brown, Tyler S","Nigoghossian, Caroline Der","Zidar, David A","Haythe, Jennifer","Brodie, Daniel","Beckman, Joshua A","Kirtane, Ajay J","Stone, Gregg W","Krumholz, Harlan M","Parikh, Sahil A","32201335"],"abstract":["The coronavirus disease-2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 that has significant implications for the cardiovascular care of patients. First, those with COVID-19 and preexisting cardiovascular disease (CVD) have an increased risk of severe disease and death. Second, infection has been associated with multiple direct and indirect cardiovascular complications including acute myocardial injury, myocarditis, arrhythmias and venous thromboembolism. Third, therapies under investigation for COVID-19 may have cardiovascular side effects. Fourth, the response to COVID-19 can compromise the rapid triage of non-COVID-19 patients with cardiovascular conditions. Finally, the provision of cardiovascular care may place health care workers in a position of vulnerability as they become host or vectors of virus transmission. We hereby review the peer-reviewed and preprint literature pertaining to cardiovascular considerations related to COVID-19 and highlight gaps in knowledge that require further study pertinent to patients, health care workers, and health systems."],"journal":"J Am Coll Cardiol","authors":["Driggin, Elissa","Madhavan, Mahesh V","Bikdeli, Behnood","Chuich, Taylor","Laracy, Justin","Bondi-Zoccai, Giuseppe","Brown, Tyler S","Nigoghossian, Caroline Der","Zidar, David A","Haythe, Jennifer","Brodie, Daniel","Beckman, Joshua A","Kirtane, Ajay J","Stone, Gregg W","Krumholz, Harlan M","Parikh, Sahil A"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32201335","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.jacc.2020.03.031","keywords":["cardiovascular therapy","coronavirus","health system"],"topics":["Prevention"],"weight":1,"_version_":1666138492402401280,"score":267.86118},{"pmid":32363334,"pmcid":"PMC7194983","title":"Cardiovascular Collapse in COVID-19 Infection: The Role of Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO).","text":["Cardiovascular Collapse in COVID-19 Infection: The Role of Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO).","COVID-19 has been associated with cardiovascular complications including acute cardiac injury, heart failure and cardiogenic shock. The role of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) in the event of COVID-19-associated cardiovascular collapse has not yet been established. We reviewed existing literature surrounding the role of VA-ECMO in the treatment of coronavirus-related cardiovascular collapse. COVID-19 is associated with higher incidence of cardiovascular complications compared to previous coronavirus outbreaks (SARS-CoV, MERS-CoV). We found only one case report from China where COVID-19-associated fulminant myocarditis and cardiogenic shock (CS) was successfully rescued using VA-ECMO as a bridge to recovery (BTR). We identified potential clinical scenarios (cardiac injury, myocardial infarction with and without obstructive coronary artery disease, viral myocarditis, and decompensated heart failure) leading to CS and risk factors for poor/uncertain benefit (age, sepsis, mixed/predominantly vasodilatory shock, prothrombotic state and/or coagulopathy, severe acute respiratory distress syndrome, multi-organ failure or high-risk prognostic scores) specific to using VA-ECMO as BTR in COVID-19 infection. Additional considerations and proposed recommendations specific to the COVID-19 pandemic were formulated with guidance from published data and expert consensus. A small subset of patients with cardiovascular complications from COVID-19 infection may progress to refractory CS. Accepting that resource scarcity may be the overwhelming concern for healthcare systems during this pandemic, VA-ECMO can be considered in highly selected cases of refractory CS and echocardiographic evidence of biventricular failure. The decision to initiate this therapy should take into consideration availability of resources, perceived benefit as well as risks of transmitting disease.","CJC Open","Chow, Justin","Alhussaini, Anhar","Calvillo-Arguelles, Oscar","Billia, Filio","Luk, Adriana","32363334"],"abstract":["COVID-19 has been associated with cardiovascular complications including acute cardiac injury, heart failure and cardiogenic shock. The role of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) in the event of COVID-19-associated cardiovascular collapse has not yet been established. We reviewed existing literature surrounding the role of VA-ECMO in the treatment of coronavirus-related cardiovascular collapse. COVID-19 is associated with higher incidence of cardiovascular complications compared to previous coronavirus outbreaks (SARS-CoV, MERS-CoV). We found only one case report from China where COVID-19-associated fulminant myocarditis and cardiogenic shock (CS) was successfully rescued using VA-ECMO as a bridge to recovery (BTR). We identified potential clinical scenarios (cardiac injury, myocardial infarction with and without obstructive coronary artery disease, viral myocarditis, and decompensated heart failure) leading to CS and risk factors for poor/uncertain benefit (age, sepsis, mixed/predominantly vasodilatory shock, prothrombotic state and/or coagulopathy, severe acute respiratory distress syndrome, multi-organ failure or high-risk prognostic scores) specific to using VA-ECMO as BTR in COVID-19 infection. Additional considerations and proposed recommendations specific to the COVID-19 pandemic were formulated with guidance from published data and expert consensus. A small subset of patients with cardiovascular complications from COVID-19 infection may progress to refractory CS. Accepting that resource scarcity may be the overwhelming concern for healthcare systems during this pandemic, VA-ECMO can be considered in highly selected cases of refractory CS and echocardiographic evidence of biventricular failure. The decision to initiate this therapy should take into consideration availability of resources, perceived benefit as well as risks of transmitting disease."],"journal":"CJC Open","authors":["Chow, Justin","Alhussaini, Anhar","Calvillo-Arguelles, Oscar","Billia, Filio","Luk, Adriana"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32363334","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.cjco.2020.04.003","keywords":["extracorporeal membrane oxygenation","cardiogenic shock","coronavirus","mechanical circulatory support","myocarditis"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138496055640065,"score":258.82397},{"pmid":32425328,"pmcid":"PMC7229739","title":"Cardiovascular implications of the COVID-19 pandemic: a global perspective.","text":["Cardiovascular implications of the COVID-19 pandemic: a global perspective.","The Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), represents the pandemic of the century, with approximately 3.5 million cases and 250,000 deaths worldwide as of May 2020. Although respiratory symptoms usually dominate the clinical presentation, COVID-19 is now known to also have potentially serious cardiovascular consequences, including myocardial injury, myocarditis, acute coronary syndromes, pulmonary embolism, stroke, arrhythmias, heart failure, and cardiogenic shock. The cardiac manifestations of COVID-19 might be related to the adrenergic drive, systemic inflammatory milieu and cytokine-release syndrome caused by SARS-CoV-2, direct viral infection of myocardial and endothelial cells, hypoxia due to respiratory failure, electrolytic imbalances, fluid overload, and side effects of certain COVID-19 medications. COVID-19 has profoundly reshaped usual care of both ambulatory and acute cardiac patients, by leading to the cancellation of elective procedures and by reducing the efficiency of existing pathways of urgent care, respectively. Decreased utilization of healthcare services for acute conditions by non-COVID-19 patients has also been reported and attributed to concerns about acquiring in-hospital infection. Innovative approaches that leverage modern technologies to tackle the COVID-19 pandemic have been introduced, which include telemedicine, dissemination of educational material over social media, smartphone apps for case tracking, and artificial intelligence for pandemic modelling, among others. This article provides a comprehensive overview of the pathophysiology and cardiovascular implications of COVID-19, its impact on existing pathways of care, the role of modern technologies to tackle the pandemic, and a proposal of novel management algorithms for the most common acute cardiac conditions.","Can J Cardiol","Boukhris, Marouane","Hillani, Ali","Moroni, Francesco","Annabi, Mohamed Salah","Addad, Faouzi","Ribeiro, Marcelo Harada","Mansour, Samer","Zhao, Xiaohui","Ybarra, Luiz Fernando","Abbate, Antonio","Vilca, Luz Maria","Azzalini, Lorenzo","32425328"],"abstract":["The Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), represents the pandemic of the century, with approximately 3.5 million cases and 250,000 deaths worldwide as of May 2020. Although respiratory symptoms usually dominate the clinical presentation, COVID-19 is now known to also have potentially serious cardiovascular consequences, including myocardial injury, myocarditis, acute coronary syndromes, pulmonary embolism, stroke, arrhythmias, heart failure, and cardiogenic shock. The cardiac manifestations of COVID-19 might be related to the adrenergic drive, systemic inflammatory milieu and cytokine-release syndrome caused by SARS-CoV-2, direct viral infection of myocardial and endothelial cells, hypoxia due to respiratory failure, electrolytic imbalances, fluid overload, and side effects of certain COVID-19 medications. COVID-19 has profoundly reshaped usual care of both ambulatory and acute cardiac patients, by leading to the cancellation of elective procedures and by reducing the efficiency of existing pathways of urgent care, respectively. Decreased utilization of healthcare services for acute conditions by non-COVID-19 patients has also been reported and attributed to concerns about acquiring in-hospital infection. Innovative approaches that leverage modern technologies to tackle the COVID-19 pandemic have been introduced, which include telemedicine, dissemination of educational material over social media, smartphone apps for case tracking, and artificial intelligence for pandemic modelling, among others. This article provides a comprehensive overview of the pathophysiology and cardiovascular implications of COVID-19, its impact on existing pathways of care, the role of modern technologies to tackle the pandemic, and a proposal of novel management algorithms for the most common acute cardiac conditions."],"journal":"Can J Cardiol","authors":["Boukhris, Marouane","Hillani, Ali","Moroni, Francesco","Annabi, Mohamed Salah","Addad, Faouzi","Ribeiro, Marcelo Harada","Mansour, Samer","Zhao, Xiaohui","Ybarra, Luiz Fernando","Abbate, Antonio","Vilca, Luz Maria","Azzalini, Lorenzo"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425328","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.cjca.2020.05.018","locations":["hypoxia"],"topics":["Prevention"],"weight":1,"_version_":1667352728791154688,"score":256.9542},{"pmid":32395790,"title":"COVID-19 and Cardiovascular diseases. Scoping review study.","text":["COVID-19 and Cardiovascular diseases. Scoping review study.","BACKGROUND: Many patients with COVID-19 have pre-existing cardiovascular (CV) co-morbidities or develop acute heart damage during the course of the disease. OBJECTIVES: To study the risk of COVID-19 infection in the presence of preexisting CV diseases and to describe new CV manifestations during COVID-19. METHODS: A \"scoping review\" was carried out via PubMed, to synthesize the results of research currently published on this subject. RESULTS: Patients with cardiovascular disease were at greater risk of developing COVID-19, especially in its severe form. These patients were five to ten times more at risk of death. Cardiac manifestations, de novo, were dominated by acute myocardial damage, defined by a significant elevation of cardiac troponins. These occurred in 7 to 17% of hospitalized patients. The presence of a new heart lesion in patients with COVID-19 was consistently associated with a poor prognosis. CONCLUSION: Given the enormous cardiovascular challenge posed by the COVID-19 pandemic and the prognostic impact of heart damage, additional research at a high level of evidence will be necessary.","Tunis Med","Yahia, Faten","Zakhama, Lilia","Ben Abdelaziz, Ahmed","32395790"],"abstract":["BACKGROUND: Many patients with COVID-19 have pre-existing cardiovascular (CV) co-morbidities or develop acute heart damage during the course of the disease. OBJECTIVES: To study the risk of COVID-19 infection in the presence of preexisting CV diseases and to describe new CV manifestations during COVID-19. METHODS: A \"scoping review\" was carried out via PubMed, to synthesize the results of research currently published on this subject. RESULTS: Patients with cardiovascular disease were at greater risk of developing COVID-19, especially in its severe form. These patients were five to ten times more at risk of death. Cardiac manifestations, de novo, were dominated by acute myocardial damage, defined by a significant elevation of cardiac troponins. These occurred in 7 to 17% of hospitalized patients. The presence of a new heart lesion in patients with COVID-19 was consistently associated with a poor prognosis. CONCLUSION: Given the enormous cardiovascular challenge posed by the COVID-19 pandemic and the prognostic impact of heart damage, additional research at a high level of evidence will be necessary."],"journal":"Tunis Med","authors":["Yahia, Faten","Zakhama, Lilia","Ben Abdelaziz, Ahmed"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32395790","source":"PubMed","week":"202020|May 11 - May 17","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666627827965886466,"score":256.75854},{"pmid":32403242,"title":"Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review.","text":["Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review.","In early December 2019, the coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged in Wuhan, China. As of May 10th, 2020, a total of over 4 million COVID-19 cases and 280,000 deaths have been reported globally, reflecting the raised infectivity and severity of this virus. Amongst hospitalised COVID-19 patients, there is a high prevalence of established cardiovascular disease (CVD). There is evidence showing that COVID-19 may exacerbate cardiovascular risk factors and preexisting CVD or may lead to cardiovascular complications. With intensive care units operating at maximum capacity and such staggering mortality rates reported, it is imperative during this time-sensitive COVID-19 outbreak to identify patients with an increased risk of adverse outcomes and/or myocardial injury. Preliminary findings from COVID-19 studies have shown the association of biomarkers of acute cardiac injury and coagulation with worse prognosis. While these biomarkers are recognised for CVD, there is emerging prospect that they may aid prognosis in COVID-19, especially in patients with cardiovascular comorbidities or risk factors that predispose to worse outcomes. Consequently, the aim of this review is to identify cardiovascular prognostic factors associated with morbidity and mortality in COVID-19 and to highlight considerations for incorporating laboratory testing of biomarkers of cardiovascular performance in COVID-19 to optimise outcomes.","Viruses","Aboughdir, Maryam","Kirwin, Thomas","Abdul Khader, Ashiq","Wang, Brian","32403242"],"abstract":["In early December 2019, the coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged in Wuhan, China. As of May 10th, 2020, a total of over 4 million COVID-19 cases and 280,000 deaths have been reported globally, reflecting the raised infectivity and severity of this virus. Amongst hospitalised COVID-19 patients, there is a high prevalence of established cardiovascular disease (CVD). There is evidence showing that COVID-19 may exacerbate cardiovascular risk factors and preexisting CVD or may lead to cardiovascular complications. With intensive care units operating at maximum capacity and such staggering mortality rates reported, it is imperative during this time-sensitive COVID-19 outbreak to identify patients with an increased risk of adverse outcomes and/or myocardial injury. Preliminary findings from COVID-19 studies have shown the association of biomarkers of acute cardiac injury and coagulation with worse prognosis. While these biomarkers are recognised for CVD, there is emerging prospect that they may aid prognosis in COVID-19, especially in patients with cardiovascular comorbidities or risk factors that predispose to worse outcomes. Consequently, the aim of this review is to identify cardiovascular prognostic factors associated with morbidity and mortality in COVID-19 and to highlight considerations for incorporating laboratory testing of biomarkers of cardiovascular performance in COVID-19 to optimise outcomes."],"journal":"Viruses","authors":["Aboughdir, Maryam","Kirwin, Thomas","Abdul Khader, Ashiq","Wang, Brian"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32403242","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/v12050527","keywords":["covid-19","sars-cov-2","cardiovascular disease","coronavirus"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666950579832750080,"score":251.81155}]}